Microdosing with the Optejet ® dispenser. The technology underlying therapeutic advancements in progressive myopia, presbyopia, and mydriasis.
Microdosing with the MicroPine Optejet® dispenser.
The technology underlying therapeutic advances in myopia, glaucoma, eye comfort, and mydriasis.
Eyedropper bottles may consistently overdose the eye with 30-50 μL of toxic preservatives and pharmaceutical ingredients when the eye’s natural, physiologic tear film capacity is only 6-8 μL. With the Optejet® dispenser, medications become more EFFECTIVE as self-administration is both simpler and more reliable. Products delivered in the Optejet® are also SAFE due to lower amounts of drug entering the blood stream with fewer side effects on the eyes. The SMART technology accompanying the Optejet® helps patients manage their therapy with reminders and therapy adherence measures.
Technology Designed to be
REAL PATIENTS USING EYEDROPPERS
Proper self-administration of eye drops requires eye-hand coordination and sufficient vision which may be an issue for an estimated 80% of patients. In published studies, even patients who believe they are taking eye drops correctly often overestimate their success and two-thirds of the time multiple drops are needed to successfully get the medication onto the eye. 4,5
These videos are of actual patients demonstrating how they self-administered their eye drops for a board-certified ophthalmologist.
4. Burns E, Mulley GP. Practical problems with eye-drops among elderly ophthalmology outpatients. Age Ageing. 1992;21(3):168–170.
5. F Schwartz, Gail & A Quigley, Harry. (2008). Adherence and Persistence with Glaucoma Therapy. Survey of ophthalmology. 53 Suppl1. S57-68. 10.1016/j.survophthal.2008.08.002.
An overdose of drugs in the eye is often associated with many ocular side effects such as hyperemia, redness, discomfort, foreign body sensation, pigment discoloration, periorbital dermatitis, and others. For certain topical medications, there are also major cardiovascular side effects such as bradycardia and arrhythmia that can result from applying too much product to the eye.6
High precision microdosing with the Optejet® is designed to delivers a targeted physiologic dose of 6-8 µL, uniformly coating the corneal surface rather than the conjunctiva in order to reduce collateral tissue exposure. The Optejets® targeting is focused on the cornea where 80% of intraocular drug penetration occurs, minimizing run-off and making for potentially safer and neater delivery of medication.
6. American Academy of Ophthalmology (AAO). “Wouldn’t it be great if eyedrops didn’t spill out of your eyes?.” ScienceDaily. ScienceDaily, 13 November 2017.
Eyenovia is developing smart electronics inside the Optejet® and mobile e-health technology that may transform compliance and chronic disease management by empowering patients and physicians with access to real-time monitoring and compliance data for a more intelligent and personalized therapeutic paradigm.